Study summary
Adding nivolumab to chemoradiation after surgery improved disease-free survival for high-risk cancers
63.1%disease-free at 3 years, vs 52.5% without nivolumab
What was tested
Nivolumab added to postoperative cisplatin-radiation, against cisplatin-radiation alone, for high-risk head and neck squamous cell cancer after surgery (summarized in a 2026 systematic review).
What they found
- 3-year disease-free survival was 63.1% vs 52.5%.
- Survival data were not yet mature.
What it means
A second immunotherapy strategy around surgery, for people at the highest risk of recurrence.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.